Poisons List Amendment Order 2000 (TAS)

Poisons List Amendment Order 2000

I make the following order under section 15(1) of the Poisons Act 1971 .10 March 2000

judy jackson

Minister for Health and Human Services

1Short titleThis order may be cited as the Poisons List Amendment Order 2000 . 2CommencementThis order takes effect on the day on which its making is notified in the Gazette or on 17 March 2000, whichever is the later. 3Principal OrderIn this order, the Poisons List Order 1998 is referred to as the Principal Order. 4Schedule 2 amended (Medicinal Poisons) Schedule 2 to the Principal Order is amended as follows: (a) by inserting after item 2003 the following:

2003M.  Amorolfine for topical use in preparations containing 0.25% or less of amorolfine.

(b) by omitting item 2062 and substituting the following:

2062.  Indomethacin in preparations for external use containing 1% or less of indomethacin.

(c) by omitting item 2066 and substituting the following:

2066.	Isosorbide dinitrate except when included in Schedule 4 .
2066E.	Isosorbide mononitrate except when included in Schedule 4 .

(d) by inserting after item 2067 the following:

2067B.  Ketoprofen in preparations for dermal use.

(e) by inserting after item 2071 the following:

2071J.  Lodoxamide in preparations for ophthalmic use.

(f) by omitting item 2078 and substituting the following:

2078.	Methoxamine except –
(a) when included in Schedule 4 ; or
(b) in preparations for external use containing 1% or less of methoxamine.

(g) by omitting item 2086 ; (h) by omitting item 2100 and substituting the following:

2100.  Piroxicam in preparations for dermal use containing 1% or less of piroxicam.

(i) by omitting item 2114 and substituting the following:

2114.  Sodium cromoglycate in preparations for nasal or ophthalmic use.

5Schedule 3 amended (Potent Substances) Schedule 3 to the Principal Order is amended as follows: (a) by omitting item 3004 and substituting the following:

3004.  Amorolfine for topical use except when included in Schedule 2 .

(b) by omitting item 3005M and substituting the following:

3005M.  Beclomethasone in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the treatment of seasonal allergic rhinitis in adults and children 12 years and over.

(c) by omitting item 3008E and substituting the following:

3008E.  Budesonide in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the treatment of seasonal allergic rhinitis in adults and children 12 years and over.

(d) by omitting item 3010 ; (e) by omitting item 3012 and substituting the following:

3012.  Cimetidine for the relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days’ supply.

(f) by inserting after item 3017 the following:

3017S.  Diclofenac in divided preparations for oral use containing 25mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units.

(g) by omitting item 3025 and substituting the following:

3025.  Famotidine for the relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days’ supply.

(h) by omitting item 3027M and substituting the following:

3027M.  Flunisolide in aqueous nasal sprays delivering 25 micrograms or less of flunisolide per actuation when the maximum recommended daily dose is no greater than 200 micrograms and when packed in a primary pack containing 200 actuations or less, for the treatment of seasonal allergic rhinitis in adults and children 12 years and over.

(i) by omitting item 3029 ; (j) by inserting after subparagraph (ii) in paragraph (b) of item 3032 the following:

3033.  Inositol nicotinate.

(k) by omitting item 3034 and substituting the following:

3034.  Insulins.

(l) by inserting after item 3035 the following:

3035M.  Ketoprofen in divided preparations for oral use containing 25mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.

(m) by inserting after item 3038 the following:

3038J.  Metoclopramide when compounded with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

(n) by omitting item 3039E and substituting the following:

3039E.  Minoxidil in preparations for dermal use containing 5% or less of minoxidil.

(o) by omitting item 3041 and substituting the following:

3041.  Nizatidine for the relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days’ supply.

(p) by inserting after item 3047 the following:

3047S.  Prochlorperazine tablets when manufactured, packed and labelled for buccal use, only for the treatment of nausea associated with migraine, in packs containing not more than 10 tablets.

(q) by omitting item 3050 and substituting the following:

3050.  Ranitidine for the relief of symptoms of gastro-oesophageal reflux, in packs containing not more than 14 days’ supply.

6Schedule 4 amended (Restricted Substances) Schedule 4 to the Principal Order is amended as follows: (a) by omitting item 40064 and substituting the following:

40064.  Amorolfine except when included in Schedule 2 or 3 .

(b) by inserting after item 40074 the following:

40074M.  Ancestim.

(c) by omitting item 40080 and substituting the following:

40080.  Antigens for human use by injection, except when separately specified in this Schedule.

(d) by omitting item 40083 and substituting the following:

40083.  Antisera (immunosera) for human use by injection except when separately specified in these Schedules.

(e) by omitting item 40143 and substituting the following:

40143.	Bismuth compounds for cosmetic use except –
(a) bismuth citrate when incorporated in hair-colourant preparations in concentrations of 0.5% or less; or
(b) bismuth oxychloride.
40143C.	Bismuth compounds for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3% or less of bismuth.

(f) by inserting after item 40160 the following:

40160S.  Brucine for human therapeutic use.

(g) by omitting item 40209 and substituting the following:

40209.  Cefodizime.

(h) by inserting after item 40219 the following:

40219C.  Celecoxib.

(i) by inserting after item 40341 the following:

40341S.  Danthron for human use.

(j) by omitting item 40376 and substituting the following:

40376.  Diclofenac except when included in Schedule 2 or 3 .

(k) by inserting after item 40422 the following:

40423.  Dirithromycin.

(l) by omitting item 40452 and substituting the following:

40452.  Eformoterol (formoterol).

(m) by inserting after item 40463E the following:

40463M.	Epoprostenol.
40463S.	Eptifibatide.

(n) by inserting after item 40502 the following:

40502S.  Fenoldopam.

(o) by inserting after item 40518 the following:

40518J.  Fludrocortisone.

(p) by inserting after item 40521 the following:

40521E.  Flumethiazide.

(q) by inserting after item 40552 the following:

40552S.  Furaltadone.

(r) by omitting item 40565 and substituting the following:

40565.  Gentamicin.

(s) by inserting after item 40566 the following:

40566M.  Gestonorone.

(t) by inserting after item 40588 the following:

40588B.  Guanidine.

(u) by omitting item 40591 and substituting the following:

40591.  Haloperidol.

(v) by inserting after item 40609 the following:

40609M.  Hydroxyphenamate.

(w) by inserting after item 40618 the following:

40618S.  Ibandronic acid.

(x) by inserting after item 40620M the following:

40620S.  Ibutilide.

(y) by omitting item 40630 ; (z) by omitting items 40649 and 40650 and substituting the following:

40649.	Isosorbide dinitrate in preparations for injection.
40650.	Isosorbide mononitrate in preparations for injection.

(za) by omitting item 40660 and substituting the following:

40660.  Ketoprofen except when included in Schedule 2 or 3 .

(zb) by inserting after item 40674 the following:

40674E.  Leflunomide.

(zc) by omitting item 40694 and substituting the following:

40694.  Lodoxamide except when included in Schedule 2 .

(zd) by inserting after item 40747 the following:

40747S.  Methacholine salts.

(ze) by inserting after item 40759E the following:

40759S.  Methoxamine in preparations for injection.

(zf) by inserting after item 40770 the following:

40770M.  Methylthiouracil.

(zg) by omitting item 40774 and substituting the following:

40774.  Metoclopramide except when included in Schedule 3 .

(zh) by omitting item 40800 and substituting the following:

40800.  Mometasone.

(zi) by omitting item 40872 and substituting the following:

40872.  Olsalazine.

(zj) by inserting after paragraph (b) in item 40877 the following:

40877S.  Orlistat.

(zk) by omitting item 40908 and substituting the following:

40908.  Papaverine in preparations for injection.

(zl) by omitting item 40919 and substituting the following:

40919.  Pentamidine (includes pentamidine isethionate).

(zm) by omitting item 40922 and substituting the following:

40922.  Pentolinium salts.

(zn) by inserting after item 40970 the following:

40970M.  Pneumococcal vaccine.

(zo) by inserting after item 40979 the following:

40979J.  Pralidoxime.

(zp) by inserting after item 40980 the following:

40980E.  Prampine salts.

(zq) by omitting item 40999 and substituting the following:

40999.  Prochlorperazine except when included in Schedule 3 .

(zr) by inserting after item 41007 the following:

41007S.  Propentofylline.

(zs) by inserting after item 41028S the following:

41028U.	Quebracho.
41028W.	Quetiapine.

(zt) by inserting after item 41048E the following:

41048J.  Rivastigmine.

(zu) by inserting after item 41057M the following:

41057U.  Sabadilla.

(zv) by omitting item 41076 and substituting the following:

41076.  Sisomicin (sisomycin).

(zw) by inserting after item 41081 the following:

41082.  Sodium polystyrene sulphonate.

(zx) by omitting item 41083 and substituting the following:

41083.  Sodium tetradecylsulfate in preparations for injection.

(zy) by omitting item 41107 and substituting the following:

41107.  Strychnos spp. (includes strychnos nux vomica).

(zz) by inserting after item 41107M the following:

41107Q.  Sulfacetamide except when included in Schedule 3 .

(zza) by inserting after item 41125 the following:

41125S.  Telmisartan.

(zzb) by omitting item 41170 and substituting the following:

41170.  Tiludronic acid (includes disodium tiludronate).

(zzc) by inserting after item 41185 the following:

41185C.  Tolrestat.

(zzd) by inserting after item 41192 the following:

41192E.  Trazadone.

(zze) by omitting item 41206E and substituting the following:

41206E.  Trifluperidol (triperidol).

(zzf) by inserting after item 41222 the following:

41222S.  Urapidil.

(zzg) by inserting after item 41229 the following:

41229S.  Varicella vaccine.

(zzh) by inserting after item 41241 the following:

41241J.  Vinyl ether for inhalation anaesthesia.

7Schedule 5 amended (Domestic Poisons) Schedule 5 to the Principal Order is amended by omitting item 5269 and substituting:

5269.  Spinosad except in aqueous suspensions containing 12% or less of spinosad.

8Schedule 6 amended (Agricultural and Industrial Poisons) Schedule 6 to the Principal Order is amended as follows: (a) by inserting after paragraph (b) in item 6026 the following:

6026S.	Bay oil except –
(a) when packed in containers having a nominal capacity of 15ml or less fitted with a restricted flow insert, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(b) when packed in containers having a nominal capacity of 25ml or less fitted with a restricted flow insert and child-resistant closure, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(c) in preparations containing 25% or less of bay oil.

(b) by omitting item 6082 and substituting the following:

6082.	Cineole except –
(a) when packed in containers having a nominal capacity of 15ml or less fitted with a restricted flow insert, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(b) when packed in containers having a nominal capacity of 25ml or less fitted with a restricted flow insert and child-resistant closure, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(c) in preparations containing 25% or less of cineole; or
(d) in oils containing 25% or less of cineole.
6082S.	Cinnamon leaf oil except –
(a) when packed in containers having a nominal capacity of 15ml or less fitted with a restricted flow insert, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(b) when packed in containers having a nominal capacity of 25ml or less fitted with a restricted flow insert and child-resistant closure, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(c) in preparations containing 25% or less of cinnamon leaf oil.

(c) by omitting item 6087 and substituting the following:

6087.	Clove oil except –
(a) when included in Schedule 5 ; or
(b) when packed in containers having a nominal capacity of 15ml or less fitted with a restricted flow insert, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(c) when packed in containers having a nominal capacity of 25ml or less fitted with a restricted flow insert and child-resistant closure, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(d) in preparations containing 25% or less of clove oil.

(d) by omitting item 6105 and substituting the following:

6105.	Deltamethrin –
(a) in aqueous preparations containing 25% or less of deltamethrin, when no organic solvent, other than 10% or less of a glycol, is present; or
(b) in other preparations containing 3% or less of deltamethrin –
except when included in Schedule 5 .

(e) by omitting items 6165 and 6166 and substituting the following:

6165.	Eucalyptus oil except –
(a) when packed in containers having a nominal capacity of 15ml or less fitted with a restricted flow insert, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(b) when packed in containers having a nominal capacity of 25ml or less fitted with a restricted flow insert and child-resistant closure, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(c) in preparations containing 25% or less of eucalyptus oil.
6166.	Eugenol except –
(a) when included in Schedule 5 ; or
(b) when packed in containers having a nominal capacity of 15ml or less fitted with a restricted flow insert, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(c) when packed in containers having a nominal capacity of 25ml or less fitted with a restricted flow insert and child-resistant closure, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(d) in preparations containing 25% or less of eugenol.

(f) by omitting item 6222 and substituting the following:

6222.	Lambda-cyhalothrin –
(a) in aqueous preparations containing 25% or less of microencapsulted lambda-cyhalothrin; or
(b) in other preparations containing 1% or less of lambda-cyhalothrin –
except when included in Schedule 5 .

(g) by omitting item 6233 and substituting the following:

6233.	Melaleuca oil except –
(a) when packed in containers having a nominal capacity of 15ml or less fitted with a restricted flow insert, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(b) when packed in containers having a nominal capacity of 25ml or less fitted with a restricted flow insert and child-resistant closure, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(c) in preparations containing 25% or less of melaleuca oil.

(h) by inserting after item 6282 the following:

6282S.	Pennyroyal oil except –
(a) when packed in containers having a nominal capacity of 15ml or less fitted with a restricted flow insert and child-resistant closure, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(b) in preparations containing 4% or less of d-pulegone.

(i) by inserting after item 6318 the following:

6318M.  d-Pulegone except in preparations containing 4% or less of d-pulegone.

(j) by inserting after paragraph (b) in item 6328 the following:

6328M.	Sage oil (Dalmatian) except –
(a) when packed in containers having a nominal capacity of 15ml or less fitted with a restricted flow insert and child-resistant closure, and labelled with the warnings –
"KEEP OUT OF REACH OF CHILDREN"; and
"NOT TO BE TAKEN"; or
(b) in preparations containing 4% or less of thujone.

(k) by omitting item 6329 and substituting the following:

6329.  Salinomycin in animal feed premixes containing 12% or less of antibiotic substances.

(l) by inserting after item 6366 the following:

6366M.  Thujone except in preparations containing 4% or less of thujone.

9Schedule 7 amended (Dangerous Poisons) Schedule 7 to the Principal Order is amended as follows: (a) by omitting item 7033 and substituting the following:

7033.	Brucine except –
(a) when included in Schedule 4 ; or
(b) in concentrations of 0.02% or less for the denaturation of alcohol.

(b) by inserting after item 7142 the following:

7142M.  Lithium perfluorooctane sulfonate except in sealed bait stations containing 1% or less of lithium perfluorooctane sulfonate.

(c) by omitting item 7202 and substituting the following:

7202.  Strychnine except when included in Schedule 4 .

Displayed and numbered in accordance with the Rules Publication Act 1953.

Notified in the Gazette on 15 March 2000

This order is administered in the Department of Health and Human Services.

EXPLANATORY NOTE

(This note is not part of the order) This order amends the